摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-formamido-4-methylcoumarin | 144900-79-8

中文名称
——
中文别名
——
英文名称
7-formamido-4-methylcoumarin
英文别名
N-(4-methyl-2-oxochromen-7-yl)formamide
7-formamido-4-methylcoumarin化学式
CAS
144900-79-8
化学式
C11H9NO3
mdl
——
分子量
203.197
InChiKey
VFBHJKAPHXOLCC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    458.8±40.0 °C(Predicted)
  • 密度:
    1.338±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    15
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    55.4
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    7-formamido-4-methylcoumarin三光气三乙胺 作用下, 以 四氢呋喃二氯甲烷 为溶剂, 反应 28.5h, 生成 N-(4-methyl-2-oxo-2H-chromen-7-yl)-N'-(4-trifluoromethyl)selenourea
    参考文献:
    名称:
    硒代香豆素作为新型多靶点抗增殖剂:合成,生物学评估和计算机计算
    摘要:
    本文中,我们报告了基于香豆素骨架与有机硒基序杂交的新型抗增殖剂的直接制备方法。获得了三个家族:异壬香氰酸酯,硒代氨基甲酸酯和硒脲。这些杂化结构的主要目的是开发具有多目标作用模式的新型抗增殖剂。 观察到有机硒支架的性质与抗增殖活性之间有很强的相关性。因此,尽管硒代氨基甲酸酯被证明是无活性的或适度的抗增殖剂,但异硒氰酸氰酸酯和大多数硒脲却表现出较强的抗增殖剂的作用,GI 50值在低微摩尔范围内。有趣的是,发现某些化合物对肿瘤细胞系具有良好的选择性。此外,观察到肿瘤细胞的ROS水平增加,因此,这些促氧化剂物质可能参与其作用方式。总体而言,发现标题化合物不是P-糖蛋白的底物,P-糖蛋白在许多癌细胞中过度表达,是排毒的一种方式,因此会产生耐药性。 电脑计算表明,本文制备的硒代衍生物可能与HDAC8的活性位点发生强烈相互作用,因此可能是组蛋白脱乙酰基酶8的潜在抑制剂。对HDAC8的体外评估表明,硒代脲
    DOI:
    10.1016/j.ejmech.2019.06.073
  • 作为产物:
    描述:
    7-氨基-4-甲基香豆素甲酰氯N,N-二异丙基乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 1.0h, 以5%的产率得到7-formamido-4-methylcoumarin
    参考文献:
    名称:
    Identification of Tissue-Restricted Bioreaction Suitable for in Vivo Targeting by Fluorescent Substrate Library-Based Enzyme Discovery
    摘要:
    Tissue-restricted bioreactions can be utilized to design chemical-biological tools and prodrugs. We have developed a fluorescent-substrate-library-based enzyme discovery approach to screen tissue extracts for enzymatic activities of interest. Assay-positive candidate proteins were identified by diced electrophoresis gel assay followed by peptide mass fingerprinting. We discovered that pyruvyl anilide is specifically hydrolyzed by carboxylesterase 2 (CES2), which is predominantly localized in the liver and kidney. We show that the pyruvyl targeting group/CES2 enzyme pair can be used to deliver the 7-amino-4-methylcoumarin fluorophore specifically to the liver and kidney in vivo. Our screening approach should be useful to find other masking group/enzyme pairs suitable for development of fluorescent substrates and prodrugs.
    DOI:
    10.1021/jacs.5b05884
点击查看最新优质反应信息

文献信息

  • A Facile, Versatile, and Highly Efficient Strategy for Peroxynitrite Bioimaging Enabled by Formamide Deformylation
    作者:Xilei Xie、Guangzhao Liu、Xingxing Su、Yong Li、Yawen Liu、Xiaoyun Jiao、Xu Wang、Bo Tang
    DOI:10.1021/acs.analchem.9b01175
    日期:2019.5.21
    Peroxynitrite (ONOO–) is attracting increasing attention due to its involvement in multiple facets of pathophysiological processes. However, ONOO– bioimaging is still challenging due to (1) the lack of highly specific reaction triggers, (2) the tedious and low-yielding synthesis of current sophisticated probes, and (3) the lack of availability of a versatile chemical strategy. To address these challenges, on the basis of amine formylation/deformylation chemistry, we have developed a novel strategy for ONOO– bioimaging. As proof of principle, we designed, synthesized, and evaluated four novel fluorescent probes equipped with the formamide functionality. Although they feature distinctly different fluorophore classes, all probes can be synthesized in one step in high yields and exhibit particularly specific, highly sensitive, and rapid responses to ONOO–. The bioimaging capability is well demonstrated by successfully visualizing ONOO– fluctuation in live cells and major organs of mice suffering from paraquat poisoning. The proposed strategy has proved to be a facile, versatile, and highly efficient methodology for ONOO– visualization, which will greatly facilitate ONOO– biochemistry and pathophysiology.
    过氧亚硝酸盐(ONOO–)因其在病理生理过程中的多重作用而越来越受到关注。然而,由于(1)缺乏高特异性的反应触发剂,(2)目前复杂探针的合成过程繁琐且产率低,以及(3)缺乏通用的化学策略,ONOO–生物成像仍然面临挑战。为了解决这些问题,我们基于胺的甲酰化/去甲酰化化学,开发了一种用于ONOO–生物成像的新策略。作为原理的证明,我们设计、合成并评估了四种具有甲酰胺功能的荧光探针。尽管它们具有明显不同的荧光团类别,但所有探针均可在一步内高产率合成,并对ONOO–表现出特别特异、高灵敏和快速的响应。通过成功可视化因巴拉克毒素中毒的小鼠活细胞和主要器官中的ONOO–波动,生物成像能力得到了良好的验证。所提出的策略已证明是一种简单、多功能且高效的ONOO–可视化方法,将极大推动ONOO–生物化学和病理生理学的发展。
  • Metal–coumarin complexes: synthesis and characterization of 7-isocyanocoumarin ligands and Mo(CO)4(7-isocyanocoumarin)2 complexes. X-ray crystal structure of Mo(CO)4(7-isocyano-4-trifluoromethylcoumarin)2
    作者:Daniel A. Freedman、Ivan Keresztes、Ann L. Asbury
    DOI:10.1016/s0022-328x(01)01186-x
    日期:2002.1
    The preparation and characterization of four different 7-isocyanocoumarin ligands is described. The four ligands are 3,4-dimethyl-7-isocyanocoumarin (Dmic), 7-isocyano-4-methylcoumarin (Mic), 3-chloro-7-isocyano-4-methylcoumarin (Cmic) and 7-isocyano-4-trifluoromethylcoumarin (Tic). Reaction of the four 7-isocyanocoumarin ligands with Mo(CO)4(pip)2 (pip=piperidine) gave the Mo(CO)4L2 complexes. IR and
    描述了四种不同的7-异氰基香豆素配体的制备和表征。四个配体是3,4-二甲基-7-异氰基香豆素(Dmic),7-异氰基-4-甲基香豆素(Mic),3-氯-7-异氰基-4-甲基香豆素(Cmic)和7-异氰基-4-三氟甲基香豆素(井字)。四个7-异氰基香豆素配体与Mo(CO)4(pip)2(pip =哌啶)的反应得到Mo(CO)4 L 2络合物。配合物的IR和UV-vis光谱表明,7-异氰基香豆素配体比简单的芳族异氰化物配体具有更强的π-酸。四个Mo(CO)4 L的UV-vis光谱中存在一个很强的可见光吸收带,该吸收带分配给金属到配体的电荷转移(MLCT)跃迁。2个复合体。在室温下,在二氯甲烷溶液中,对Mic,Cmic和Dmic复合物的MLCT带进行激发,产生橙黄色发射。Mo(CO)4(Mic)2与P(Ph)3在THF溶液中光解产生Mo(CO)3(PPh 3)(Mic)2。
  • NPY Y5 ANTAGONIST
    申请人:KAWANISHI Yasuyuki
    公开号:US20100292500A1
    公开(公告)日:2010-11-18
    The present invention provides a pharmaceutical composition for use as art NPY Y5 receptor antagonist comprising a compound or the formula (I): wherein R 1 is lower alkyl, cycloalkyl or the like, R 2 is hydrogen, lower alkyl or the like, n is 1 or 2, X is lower alkylene, lower alkenylene, arylene, cycloalkylene or the like, Y is CONR 7 , CSNR 7 , NR 7 CO, NR 7 CS or the like, Z is lower alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl or the like and R 7 is hydrogen or lower alkyl, prodrug, pharmaceutically acceptable salt or solvate thereof.
    本发明提供了一种药物组合物,用作NPY Y5受体拮抗剂,包括化合物或式(I):其中R1为低碳基、环烷基或类似物,R2为氢、低碳基或类似物,n为1或2,X为低碳基、低烯基、芳基、环烷基或类似物,Y为CONR7、CSNR7、NR7CO、NR7CS或类似物,Z为低碳基、可选取代的碳环基、可选取代的杂环基或类似物,R7为氢或低碳基,前药、药学上可接受的盐或溶剂。
  • NPYY5 antagonists
    申请人:Shionogi&Co., Ltd.
    公开号:EP2014285A1
    公开(公告)日:2009-01-14
    The present invention provides a pharmaceutical composition for use as an NPY Y5 receptor antagonist comprising a compound of the formula (I): wherein R1 is lower alkyl, cycloalkyl or the like, R2 is hydrogen, lower alkyl or the like, n is 1 or 2, X is lower alkylene, lower alkenylene, arylene, cycloalkylene or the like, Y is CONR7, CSNR7, NR7CO, NR7CS or the like, Z is lower alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl or the like and R7 is hydrogen or lower alkyl, prodrug, pharmaceutically acceptable salt or solvate thereof
    本发明提供了一种用作 NPY Y5 受体拮抗剂的药物组合物,该组合物由式(I)化合物组成: 其中 R1 是低级烷基、环烷基或类似物、 R2 是氢、低级烷基或类似物、 n 是 1 或 2、 X 是低级烯烃、低级烯烃、芳基、环烷烃或类似物、 Y 是 CONR7、CSNR7、NR7CO、NR7CS 或类似物、 Z 是低级烷基、任选取代的碳环烷基、任选取代的杂环烷基或类似物,R7 是氢或低级烷基、 其原药、药学上可接受的盐或溶液
  • [EN] PRODRUG AND FLUOREGENIC COMPOSITIONS AND METHODS FOR USING THE SAME<br/>[FR] PROMÉDICAMENT ET COMPOSITIONS FLUOROGÉNIQUES ET LEURS PROCÉDÉS D'UTILISATION
    申请人:UNIV CALIFORNIA
    公开号:WO2010011684A3
    公开(公告)日:2010-04-29
查看更多